ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Summary

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression? What adverse events do participants have when taking ACP-211?

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Major Depressive Disorder (MDD)
• Depressive Disorder, Treatment-Resistant

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 65 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

ACADIA Pharmaceuticals Inc.

Last updated on ClinicalTrials.gov

October 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites